Hengrui Pharma has granted Merck exclusive rights to develop, manufacture and commercialize HRS-5346 worldwide, excluding Greater China region
New facility will support plans to advance J&J’s portfolio and pipeline of transformational medicines for cancer, immune-mediated and neurological diseases
Company expects to begin building four more domestic manufacturing sites this year and add 13,000 high-wage manufacturing and construction jobs in America
The launch follows the approval from the Medicines and Healthcare Products Regulatory Agency (MHRA), U.K.
The Formulation & Technology Centre intends to function as a technology storefront, offering advanced formulation and processing solutions to address the growing demand for complex drug formulations
Amgen India investment totals $200 million through 2025
Innovative chronic pain treatment receives IP protection in India's $55 billion pharmaceutical market
The company anticipates 2025 worldwide sales to be between $64.1 billion and $65.6 billion
The stable raw materials prices, focused cost improvement initiatives and intensified customer acquisitions helped the company to improve its margin profile
Profit after Taxes registered strong growth of 22% to Rs. 162 crores versus Rs. 134 crores in Q3 FY24
Subscribe To Our Newsletter & Stay Updated
